Friday 18 Apr, 2025 10:51 AM
Site map | Locate Us | Login
   Infosys Q4 PAT rises 3% QoQ to Rs 7,038 cr; declares dividend of Rs 22/sh    HDFC Life Q4 PAT climbs 16% YoY to Rs 476 cr    HDFC AMC rises after Q4 PAT jumps 18% YoY to Rs 639 cr; declares final dividend of Rs 90/sh    Sonata Software drops amid lower Q4 revenue guidance    AGI Infra's housing project in Punjab gets RERA registration    Home First Finance gains after raising Rs 1,250 crore    Lupin gets EIR from USFDA for Nagpur facility    Sonata Software Ltd leads losers in 'A' group    Alkem Labs' subsidiary concludes acquisition of 100% stake in Bombay Ortho    Vikram Aroma Ltd leads losers in 'B' group    Awfis Space inks pact with ECOS Mobility for offering premium corporate transportation services    Volumes spurt at Fertilizers & Chemicals Travancore Ltd counter    E2E Networks rallies after multi-fold jump in Q4 PAT to Rs 13.61 cr    Gensol Engg slumps as SEBI unplugs promoters over alleged fraud    Information Technology stocks slide 
Saravan Stocks
       
Hot Pursuit
Scrips, which has significant changes during the market hours.
Biocon unit gets U.S. FDA nod for cancer drug biosimilar
10-Apr-25   11:07 Hrs IST

This drug is used to treat multiple cancers by inhibiting VEGF (vascular endothelial growth factor), effectively cutting off blood supply to tumors.

This marks Biocon's seventh biosimilar approval in the U.S., expanding its oncology arsenal alongside OGIVRI (trastuzumab) and FULPHILA (pegfilgrastim). JOBEVNE is already being sold in Europe and Canada under the name ABEVMY.

CEO Shreehas Tambe hailed the approval as a testament to Biocon's scientific strength and mission to make affordable biologics widely available. With U.S. sales of bevacizumab hitting ~$2 billion in 2023, JOBEVNE has blockbuster potential.

Biocon is a global biopharmaceuticals company committed to enhance affordable access to complex therapies for chronic conditions like diabetes, cancer and autoimmune.

On a consolidated basis, Biocon's net profit slumped 96.20% to Rs 25.10 crore while net sales rose 6.32% to Rs 3773 crore in Q3 December 2024 over Q3 December 2023.

Shares of Biocon dropped 5.33% to Rs 305.20 on Wednesday, 9 April 2025. The Indian stock market is shut today for Shri Mahavir Jayanti.

Powered by Capital Market - Live News
   Attention Investors : Prevent Unauthorized Transactions in your demat account --> Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from CDSL on the same day........issued in the interest of investors.
   Attention Investors : Prevent unauthorised transactions in your account Update your mobile numbers/email IDs with your stock brokers / Depository Participant. Receive information of your transactions directly from Exchange / Depositories on your mobile / email at the end of the day .... Issued in the interest of Investors.
   Attention Investors : KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
   Attention Investors : No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."
Email ID: info@ssplwealth.com       Customers grievances : grievances@ssplwealth.com     Compliance officer : Mr.R Udayakumar , compliance@ssplwealth.com,  Mobile No: 7305522205
Investor Charter | Annual Return | Account Closure | RE-KYC | Disclaimer | Feed Back | Privacy Policy | Policies & Procedures | |Rights & Obligations-English| Rights & Obligations-தமிழ் | Anti Money Laundering Policy | E-Voting | CSR | Voluntary Freezing / Blocking Hit Count : 40259444
Useful Links : NSE | BSE | MCX | NSDL | CDSL | SEBI | RBI | ATTENTION INVESTOR| SMART ODR
SEBI Regn.Nos : NSE/BSE-INZ000192638 | CDSL : IN-DP-262-2016
Member IDs : NSE : 11221 | BSE : 6292 | CDSL : 12045000 | MCX : 56990 | AMFI Regn.No : 2662
Designed , Developed & Content provided by CMOTS INFOTECH.(ISO 9001:2015 certified) © Copyright 2011 All Rights Reserved. SSPL WEALTH Pvt. Ltd